Exacerbations of chronic obstructive pulmonary disease impose a considerable burden of morbidity, mortality, and health care cost. Management guidelines outlining best practice, based largely on consensus expert opinion, were produced by a number of organisations during the last decade. Current interest in the field is high. This has resulted in the publication of many further studies which have extended our understanding of the pathology involved and provided, for the first time, an evidence base for many of the therapeutic options. In this review we aim to bring the non-specialist reader up to date with current management principles and the evidence underlying such interventions.

The case history described below will be familiar to many physicians working in both primary and secondary care. This review will consider current concepts in the clinical management of an exacerbation of chronic obstructive pulmonary disease (COPD) and explore the evidence basis underlying such decisions. We conclude by posing some questions relating to the case history (see next page).

WHAT IS AN EXACERBATION?
The recent World Health Organisation document entitled Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD in terms of airflow limitation that is progressive, not fully reversible, and associated with an abnormal inflammatory response of the lung to noxious stimuli. The relentless decline in lung function is punctuated by intermittent episodes characterised by deterioration of symptoms termed “exacerbations”. Exacerbations become more frequent and severe as the severity of the underlying disease increases. In a study of patients with moderately severe disease, the median exacerbation frequency was 2.7 per year. To exacerbate, from the Latin “exacerbare” and meaning to make harsh, is generally used to imply the process of making something bad, worse. In practical terms exacerbation is a clinical diagnosis manifest by a sustained worsening of symptoms from the stable state that is acute in onset, and beyond the patient’s usual day to day variation. These symptoms typically include increased breathlessness, sputum volume and sputum purulence, perhaps accompanied by increased cough, wheeze, chest tightness, features of a cold, oedema, fatigue, or confusion. There is, however, considerable debate about the precise definition of exacerbation. While differences between definitions may seem subtle, they are of great importance in the interpretation of clinical studies. Some definitions, including a recent attempt to obtain consensus, include a health care utilisation component such that the change in symptoms must necessitate a change in treatment. However, including health care utilisation adds a number of diverse and unpredictable variables to the underlying pathophysiological mechanisms. These include local health care resources, the patient’s perception of the severity of the symptoms, and the economic and social situation of the patient. Furthermore, studies using a purely symptom based definition have illustrated that up to 50% of exacerbations go unreported to health care professionals and that these may be just as severe as reported events.

Constructing a definition is complex because exacerbations are extremely heterogeneous. A broad description is required to encompass the range of events from a worsening of symptoms in a patient with mild COPD to the life threatening episodes of respiratory failure experienced by patients with more severe underlying disease. A deterioration in symptoms beyond usual day to day variation is the common factor and it is that which is relevant to daily clinical practice.

CAUSES OF EXACERBATIONS
Most exacerbations are caused by tracheobronchial infection or pollutants and the common aetiological agents are listed in box 1. Depending on the methods of detection employed, individual percentages vary and in a proportion of exacerbations the cause remains obscure.

Respiratory viruses account for around 30% of exacerbations and the single most important viral pathogen is human rhinovirus. Viral circulation, and therefore exacerbation incidence, is more common during the winter months. In addition, cold weather causes a reduction in lung function which may interact with pollutants and viruses to further increase exacerbation frequency. Viral exacerbations are associated with greater symptoms and a longer recovery period and are therefore more severe.
The three most common bacterial isolates are *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Moraxella catarrhalis*. The role of bacteria in causing exacerbations is controversial because the same organisms may be isolated in up to 30% of patients at clinical stability. This phenomenon, termed "bacterial colonisation", is associated with continued cigarette smoking and increasing severity of underlying disease. Much of the evidence that bacteria are an important cause of exacerbations is therefore extrapolated from the benefit seen in trials of antibiotics. The presence of colonisation is not benign and may itself modulate exacerbation frequency and contribute to a more rapid decline in lung function. A recent study has suggested that exacerbation may be the result of acquiring new strains of bacteria. Sputum purulence is a reliable indicator of the presence of bacteria.

A number of studies have examined the role of pollutants at exacerbation of COPD and it has been shown that increasing air pollution correlates with higher hospital admission rates. Most data are available for ozone, but particulates and oxides of sulphur and nitrogen have also been implicated.

### IMPORTANCE OF EXACERBATIONS

Much of the morbidity and mortality in COPD may be attributed to exacerbations. Admissions to hospital due to exacerbations are increasing in frequency and account for 10% of all acute medical admissions in the UK. In-hospital mortality is approximately 10% and associated with the severity of exacerbation; especially refractory hypoxia, increasing age, malnutrition, and the presence of comorbidities. In addition to significant mortality, patients experiencing frequent exacerbations are known to have a poorer quality of life, and exacerbation frequency has recently been linked with an accelerated decline in lung function.

Finally, exacerbations and particularly hospitalisations in patients with more severe underlying disease account for around 70% of the direct medical costs of COPD. Exacerbations of COPD are therefore an important cause of morbidity, mortality, and health care cost.

### ASSESSMENT

In the section above we have described exacerbation of COPD as a clinical diagnosis: there is no confirmatory diagnostic test. Evaluation of the patient with a possible exacerbation therefore focuses on assessing the severity of the episode and excluding other causes for deterioration in symptoms. A full history and clinical examination are essential. It is particularly important to assess the work of breathing, considering respiratory rate and use of accessory muscles, and the presence of signs suggesting hypercapnic respiratory failure including cyanosis, flapping tremor, confusion, and the presence of peripheral oedema. Important differential diagnoses are listed in box 2 and most may be excluded in the hospital setting with a clinical history, examination, and the addition of simple investigations such as the electrocardiogram (ECG) and chest radiograph. Most published guidelines recommend a full blood count and electrolyte assay, ECG, chest radiograph, and arterial blood gas analysis. Theophylline levels are suggested for patients taking these drugs, and sputum culture and sensitivity testing is useful for those with sputum purulence. Assessment of lung function by spirometry or peak flow is not generally helpful: changes at exacerbation are small, absolute values may be misleading, and the tests are difficult to perform in patients who are acutely unwell.

Assessment of severity is useful in guiding decisions on initial treatment strategy and whether a patient requires hospital admission. A minority need hospital care and early supported discharge is a further option considered in more detail later in this review. Important factors to consider regarding the necessity for admission to hospital include the
need for therapy not available at home, comorbidities, and the lack of appropriate social support. There is no widely accepted scoring system to assess severity, pH, rather than PaCO₂, is an important marker since this reflects acute changes in alveolar ventilation. The GOLD document suggests that a pH < 7.30 represents a life threatening exacerbation. The published guidelines, all provide broadly similar recommendations on the necessity of hospital admission, and factors which should be considered are listed in box 3. These factors are also those which a primary care physician will wish to address in deciding whether or not a patient reviewed in the community requires hospital assessment.

TREATMENT

In the following section we outline the different therapies available at exacerbation of COPD and discuss the underlying rationale and evidence basis. Treatment is employed either to target the underlying pathology, or to support respiratory function while disease modifying therapies are able to act. Many national and international guidelines on the management of both stable COPD and exacerbations were published during the last decade, primarily based on consensus expert opinion. The World Health Organisation GOLD document is more recent and was the first to provide explicitly evidence based recommendations. It was last updated during 2003 and is available online at www.goldcopd.com. In the UK, further guidelines have recently been published by the National Institute for Clinical Excellence (NICE).

Inhaled bronchodilators

Inhaled bronchodilator drugs are the mainstay of treatment in stable COPD. Although the airflow obstruction in COPD is, by definition, largely irreversible; these drugs may produce considerable symptomatic benefit through mechanisms including an effect on dynamic hyperinflation. At exacerbation there may be additional bronchoconstriction, due to complex inflammatory-neural interactions, that results in further hyperinflation. It is therefore logical to increase both the dose and frequency of administration of bronchodilator agents. Current guidelines give preference to the short acting β₂-agonists such as salbutamol. The drug has a rapid onset of action, reaches peak activity at between 10 and 30 minutes, and remains effective for between four and six hours. This is a more rapid onset but shorter total duration than the anticholinergic bronchodilator ipratropium. Although in stable disease there is evidence that anticholinergics achieve superior bronchodilation, with the higher doses used at exacerbation there are no differences seen and, furthermore, a meta-analysis has shown no evidence of a synergistic effect. Despite this, guidelines recommend the addition of an anticholinergic agent when therapy with a β₂-agonist alone is insufficient to achieve improvement. A meta-analysis has shown no benefit of nebulised therapy over inhalation via a spacer device, but patients acutely short of breath may not be able to achieve an adequate inhalation technique with inhalers. Nebulised therapy is also more expensive. There is currently no evidence for a role of long acting bronchodilators in treating exacerbations. Although there are data supporting the use of intravenous salbutamol in acute severe asthma, no such evidence exists for its use at exacerbation of COPD. In addition, troublesome side effects (most commonly tremor and palpitation) are more frequently seen than with inhaled delivery due to the increased stimulation of extrapulmonary β-adrenoreceptors. Similarly, continuous nebulisation of salbutamol is not recommended. Clinically important side effects from ipratropium are rarely encountered.

Corticosteroids

Exacerbations are associated with increased airway inflammation which therefore provides a rationale for the use of anti-inflammatory corticosteroid therapy. Systemic steroids form the cornerstone of treatment in all but the mildest of exacerbations which have responded to an increase in bronchodilator medication alone. Two recent systematic reviews summarising a number of randomised trials have shown the benefit of steroids in providing a greater improvement in early forced expiratory volume in one second recovery. However, improvements in oxygenation and duration of hospitalisation were more variable and there is no evidence to support a mortality benefit. There is, however, a suggestion that the use of steroids may prolong the time to a subsequent exacerbation. The GOLD guidelines recommend a dose of 30–40 mg prednisolone continued for between 10 and 14 days. Tapering courses are not of additional benefit in asthma but the relevant studies in COPD have not been performed. Prolonging treatment is not advantageous and increases the incidence of side effects, especially hyperglycaemia. The NICE guidelines recommend that patients receiving multiple courses of oral steroids should receive prophylaxis against osteoporosis. Many physicians, in the acute setting, will give a first dose of steroid intravenously and one of the trials included in the reviews outlined above did employ and show benefit from intravenous methylprednisolone. Nebulised budesonide

Box 2: Differential diagnosis for deterioration of symptoms in a patient with stable COPD

Respiratory:
- Acute exacerbation.
- Pneumonia.
- Pneumothorax.
- Pleural effusion.
- Lung carcinoma.
- Pulmonary embolus.

Cardiac:
- Cardiac failure.
- Cardiac arrhythmia.

Other:
- Rib fracture.
- Upper airway obstruction.

Box 3: Factors suggesting hospital assessment or admission in exacerbation of COPD

- Marked increase in intensity of symptoms.
- Severe background COPD (GOLD stage IV).
- Onset of new physical signs (for example, cyanosis or oedema).
- Altered mental status.
- Failure to respond to initial medical management.
- Requirement for therapy not available at home.
- Significant comorbidities (for example, cardiac failure).
- Diagnostic uncertainty.
- Older age.
- Insufficient home support.
causes similar improvements in lung function to oral treatment but is more expensive.44 There is no role for initiating inhaled corticosteroids at the time of exacerbation, but patients already prescribed these drugs would normally continue in their use, and inhaled steroids have an important role in the prevention of exacerbation that is discussed later in this review.

**Antibiotics**

Since many exacerbations are believed to be bacterial in origin the rationale for antibiotic treatment is intuitive. The seminal work by Anthonisen et al only showed evidence of benefit from antibiotics in exacerbations characterised by at least two of the following three symptoms: increased dyspnoea, sputum purulence, or sputum volume.45 That is, there had to be a change in the character of the sputum for antibiotics to be beneficial. Sputum purulence is a reliable indicator of the presence of bacteria.46 Bacteria are a more common cause of exacerbation in those with more severe underlying disease and a community study of exacerbations in milder patients demonstrated no acceleration of recovery or reduction of relapse with antibiotics.47 Overall, a meta-analysis by Saint et al found a small but significant benefit in favour of antibiotics at exacerbation of COPD.48 The NICE guidelines have recommended that patients without sputum purulence do not require antibiotics since such exacerbations are unlikely to be bacterial in origin.49 Many different antibiotics have been employed but coverage of *H influenzae*, *S pneumoniae*, and *M catarrhalis* is required. Local susceptibility patterns and antibiotic policies must also be considered. Parenteral antibiotics are rarely necessary. Initial empiric therapy would usually employ an oral aminopenicillin, macrolide, or tetracycline agent. There are few comparative trials50 51 but the data suggest less treatment failure with newer drugs such as macrolides and quinolones, which must be balanced against the higher costs and implications for microbial resistance. Increasing problems with penicillin resistance among pneumococcal isolates, and β-lactamase producing *H influenzae* have already been noted.52 It is possible that macrolides have a greater impact on mortality,53 perhaps because of the additional anti-inflammatory properties these drugs possess.

**Methylxanthines**

Methylxanthine drugs act via a variety of mechanisms including increasing respiratory drive, improving respiratory muscle function, enhancing mucociliary clearance, and as bronchodilators. They may also possess anti-inflammatory and immunomodulatory functions. At exacerbation, the drug most commonly used is intravenous aminophylline. A recent meta-analysis considering three randomised trials and one abstract found no benefit in improvement of pulmonary function or symptoms.54 In addition to this lack of objective benefit, the drugs have problems with a narrow therapeutic interval that causes frequent gastrointestinal side effects and less common but more serious toxicities such as cardiac arrhythmia. Serum monitoring is therefore required. There are important interactions with other drugs including the quinolone antibiotics. Routine use is not recommended. Patients already taking oral preparations of methylxanthines for stable disease would normally continue on such treatments at the time of exacerbation.

**Respiratory stimulants**

The use of centrally acting respiratory stimulants, most commonly given as intravenous doxapram, has declined with the introduction of non-invasive ventilation (NIV) which has clear superiority in the management of hypercapnic respiratory failure.55 A recent Cochrane review concluded that while being the most effective respiratory stimulant, doxapram was only able to achieve minor short term improvements in blood gas tensions.56 In addition, any beneficial effects only last between 24 and 48 hours and use is limited by the common side effect of agitation. There may still be a role for the use of doxapram where NIV is considered inappropriate, as a holding measure before the introduction of NIV, or (with specialist advice) as an adjunct to NIV.

**Oxygen**

Hypoxia at exacerbation of COPD is primarily the consequence of ventilation-perfusion (V/Q) imbalance and may be life threatening, for example through cardiac arrhythmia.57 Oxygen should therefore be used to correct hypoxia in respiratory failure. This should be administered in a controlled manner, to prevent the hypercapnia which will occur in a minority of patients.58 The usual explanation for worsening hypercapnia arises from the finding that in patients with chronic hypercapnia the main stimulus to respiration is hypoxic drive. Overcorrecting the Pao2, therefore results in increasing carbon dioxide retention and acidemia.59 Studies have shown that there is little risk of carbon dioxide retention and acidemia when oxygen is delivered to achieve maximal oxygen saturations of between 90% and 92%.60 Failure to correct hypoxemia to 90% with the fraction of inspired oxygen >40% suggests the presence of additional pathology, for example pulmonary embolus, pneumonia, or atelectasis. Around 20% of patients with an exacerbation present to hospital with acidemia.61 In these patients, Pao2 is inversely proportional to pH, in other words the greater the overcorrection of Pao2 the more severe the resulting acidemia. Arterial blood gas analysis should be performed in all patients with oxygen saturations less than 90% and repeated 30 minutes after instituting or changing the amount of oxygen therapy. Current British Thoracic Society guidelines recommend that Pao2 be maintained at >7.5 kPa when pH is satisfactory, or >6.6 kPa where there is a fall in pH.62 Achieving adequate oxygenation only at the expense of deteriorating pH or rising Paco2 suggests the need for non-invasive ventilation. Venturi masks provide a more reliable oxygen concentration and are less likely to be dislodged than nasal prongs, but are not as well tolerated.63 64 Ear lobe gases may not accurately reflect the Pao2 and are not necessarily less painful.65 When prescribing nebulised therapy it is good practice to define the driving gas. Hypercapnic or acidaemic patients should receive nebulisers driven on compressed air, receiving any supplemental oxygen separately via nasal prongs, but are not as well tolerated.66 67 Ear lobe gases may not accurately reflect the Pao2 and are not necessarily less painful.68 When prescribing nebulised therapy it is good practice to define the driving gas. Hypercapnic or acidaemic patients should receive nebulisers driven on compressed air, receiving any supplemental oxygen separately via nasal cannulae. Omission of supplemental oxygen during nebulisation risks the development of hypoxaemia.

**Non-invasive ventilation**

At an exacerbation of COPD, additional bronchoconstriction may result in increased dynamic hyperinflation that can increase the work of breathing. Furthermore, there is considerable evidence that COPD is a systemic disorder, one

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Relative indications and contraindications for NIV at exacerbation of COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
<td><strong>Contraindications</strong></td>
</tr>
<tr>
<td>Exacerbation with respiratory acidemia PaO2 &lt;6 kPa and pH &lt;7.35 but &gt;7.25</td>
<td>Inability to protect airway</td>
</tr>
<tr>
<td>Respiratory rate &gt;24 breaths/min</td>
<td>Life threatening hypoxaemia</td>
</tr>
<tr>
<td></td>
<td>Haemodynamic instability</td>
</tr>
<tr>
<td></td>
<td>Impaired consciousness or agitation</td>
</tr>
<tr>
<td></td>
<td>Undrained pneumothorax</td>
</tr>
<tr>
<td></td>
<td>Inability to clear respiratory secretions</td>
</tr>
</tbody>
</table>
manifestation of which is skeletal muscle dysfunction. In patients with severe underlying disease and poor respiratory reserve an exacerbation may therefore precipitate respiratory failure. Respiratory failure is defined as PaO₂ <8 kPa or PaCO₂ >6 kPa breathing room air. When controlled oxygen therapy is not able to correct hypoxia without worsening hypercapnia and acidaemia, or in those patients presenting with acidaemia, there is a large body of evidence to demonstrate that NIV is an effective therapy. NIV refers to the provision of ventilatory support via a nasal or full face mask without the use of an endotracheal tube. Studies have shown that NIV does not necessarily improve V/Q matching and the likely mechanism is also through off-loading fatigued respiratory musculature. Recent reviews, randomised trials, and meta-analysis have demonstrated a reduction in mortality, the need for intubation, improvements in acidaemia, shorter hospital stay, and reduced complications than standard care. It is therefore also cost effective.

NIV is the treatment of choice for acute hypercapnic respiratory failure which persists after optimal care. In addition, in contrast to invasive ventilation via an endotracheal tube, NIV can be used earlier, intermittently, and it permits physiotherapy, communication, and nutrition to continue normally. It is usually administered as pressure cycled bi-level positive airway pressure (BiPAP) indicating that the inspiratory and expiratory pressures may be independently varied. Volume cycled ventilators may also be used. An appropriate flow rate of supplemental oxygen should be added to the ventilator tubing where hypoxaemia persists. NIV is not, however, an alternative to invasive ventilation when this is clinically indicated. Based on published reviews, the relative indications and contraindications of NIV at exacerbation of COPD are listed in Table 1. Successful NIV requires trained staff but can be effectively administered on a general medical ward. Between 80% and 85% of patients in whom NIV is indicated may be treated successfully. It is important to have a prior treatment plan for those who fail or do not tolerate NIV: either progression to tracheal intubation or palliation with appropriate supportive care.

Invasive ventilation
The decision to institute invasive ventilation at an exacerbation of COPD is not easy and should follow a consideration of the degree of reversibility, any comorbidities, and the prior functional status and wishes of the patient, in discussion with their carers. The main indications are acidaemia and severe or worsening hypoxia. The aim is to support ventilation while disease modifying therapies act to reverse the cause of deterioration. While intubated, bronchodilator drugs may be added to the ventilator circuit using a nebuliser or via inhaler and spacer. Steroids and antibiotics are usually administered parenterally. A full discussion of invasive ventilation in the treatment of COPD is outside the scope of this review. Mortality in the intensive care unit is approximately 20%, which is less than that seen in respiratory failure due to other causes. Previous therapeutic nihilism surrounding COPD is therefore unfounded. The ventilatory problem in COPD is primarily a mismatch between the respiratory load and the ability of the muscles to cope with that load, rather than being of gas exchange. Weaning from the ventilator can therefore be a challenging problem and NIV may have an important role in reducing weaning time, intensive care unit stay, the incidence of nosocomial pneumonia, and mortality.

Miscellaneous
A number of strategies have been suggested to aid expectoration of secretions at exacerbation of COPD. There is no evidence supporting a benefit from respiratory physiotherapy, indeed this may be harmful, and no data are available to recommend the use of saline nebulisation. Cough and expectoration have an important role in clearing secretions and therefore antitussives are contraindicated.

A Cochrane review considering the use of helium-oxygen mixture (heliox) found no evidence of benefit.

Other supportive care should be instituted which will include optimisation of fluid balance (diuretic therapy may be required where there is evidence of cardiac impairment), consideration of anticoagulation prophylaxis against venous thromboembolism (especially if polycythaemic), and perhaps nutritional supplementation for those with low body mass index. Although malnourished patients have a poorer outcome, there is no convincing evidence that this is reversed by nutritional supplementation.

Finally, for patients not responding to maximal therapy or in whom escalation of therapy is considered inappropriate, a range of palliative therapies may be instituted which may include the use of opiate drugs to relieve pre-terminal dyspnoea and distress. The ethical considerations in making such decisions are complex.

DISCHARGE
After an exacerbation of COPD and before hospital discharge a patient should have stable symptoms and blood gases, and be taking their home medication satisfactorily. Therapy should be optimised as described in the following section to reduce the potential for future exacerbation. Factors affecting readmission were investigated in the EFRAM study and found to include previous frequent admission, more severe underlying disease, and under-prescription of long term oxygen therapy where this is indicated. A follow up appointment at between four and six weeks should therefore be arranged, with repeat blood gas analysis for those having experienced respiratory failure, to guide the need for prescription of long term oxygen therapy. A number of studies, including a recent meta-analysis, have looked at early supported discharge or "hospital at home" after hospital assessment. Only around 25% of patients are suitable and while there is no change in mortality or readmission, duration of inpatient stay is reduced. Such schemes are not necessarily more cost effective.

PREVENTION
Given the considerable impact that exacerbations of COPD have on both the patient and health services there is much interest in strategies designed to reduce exacerbation
frequency and severity. In this section we review the options available and outline the supporting evidence.

One important approach in the reduction of exacerbation morbidity is the judicious use of inhaled corticosteroids. While many large studies of inhaled steroids in stable COPD have been published, exacerbation frequency was a primary end point in only one of these. This study did not find a reduction in exacerbation frequency in the steroid treated patients but did note a decrease in exacerbation severity in those patients randomised to fluticasone. Evidence for the benefit of inhaled steroids on exacerbation frequency is therefore primarily from large studies such as the ISOLDE trial. Here, a beneficial effect was observed in subjects taking fluticasone 1000 μg per day. These patients had moderately severe underlying disease, as manifest by forced expiratory volume in one second <50%, and studies in patients with more mild disease have not shown benefit. Elsewhere, it has been reported that withdrawal of inhaled steroid therapy is associated with an increased risk of exacerbation. A meta-analysis of nine trials does suggest a relative risk reduction for a decrease in exacerbation frequency in patients treated with inhaled steroids. The prescription of long term, high dose inhaled corticosteroids must be balanced against the known side effects which, while less common than with oral administration, may still be a significant problem. While it has not been shown that the use of inhaled corticosteroids increases fracture rate, there is evidence of effects on surrogate markers of bone metabolism. Similarly, there is evidence for an increased risk of cataract, skin bruising, and oral candidiasis. Oral corticosteroids do not reduce exacerbation frequency and one study has suggested that in the minority of patients taking these drugs long term the therapy may be withdrawn without an increase in exacerbations.

In addition to inhaled corticosteroids, there is evidence that the long acting bronchodilator agents, both β₂-agonists and anticholinergics, may reduce exacerbation frequency. The β₂-agonists are thought to have additional anti-inflammatory properties and there may be a synergistic action in which the β₂-agonist assists the intranuclear localisation of the glucocorticoid receptor. Clinical trials, however, tend to demonstrate an additive rather than multiplicative effect.

A Cochrane meta-analysis has reported a benefit for influenza vaccination in the reduction of exacerbation frequency in COPD. The data to support use of pneumococcal vaccine are less conclusive, though this is still recommended in the GOLD guidelines.

A meta-analysis considering prophylactic antibiotics in COPD or chronic bronchitis showed a small benefit in reducing exacerbations which must be weighed against the increased incidence of adverse events and concerns over antimicrobial resistance. Interestingly, the original studies were performed in the 1960s and there is current interest in targeting antibiotic therapy to those patients with lower airway bacterial colonisation. A recent meta-analysis of mucoysis, a class of drug rarely used in the UK, suggests a 29% reduction in exacerbations but the individual studies were of short duration and in patients with mild disease. Most of the benefit seen was with N-acetyl cysteine, which also has antioxidant properties, and further trials of this drug are currently underway. One study reported a reduction in exacerbation frequency using the immunostimulatory agent OM-85 BV, an agent based on lyophilised fractions of common respiratory pathogens, but these results have not been replicated and the preparation is not in routine use.

As described above, under-prescription of long term oxygen therapy is a risk factor for readmission to hospital and appropriate use of this therapy may therefore reduce the burden of exacerbations. Pulmonary rehabilitation has also been shown to reduce hospital admission in patients with COPD. For patients with chronic hypercapnic respiratory failure, domiciliary NIV reduces hospitalisation, though a specific effect on exacerbation frequency has not been demonstrated. A recent study has reported a benefit for domiciliary NIV in reducing admissions in patients experiencing recurrent hypercapnic exacerbations and, furthermore, that this therapy may be cost effective.

**SUMMARY**

Exacerbations of COPD impose a considerable burden on both the patient and health care system. Most exacerbations are caused by tracheobronchial infection. The diagnosis is clinical and characterised by a deterioration in the patient’s symptoms. Clinical evaluation and investigation is directed to assess the severity of the episode and exclude differential diagnoses. The mainstay of treatment is with inhaled bronchodilators and oral corticosteroids. Antibiotics are indicated where there is sputum purulence. Controlled oxygen therapy is indicated in respiratory failure and, where there is acidemia, the use of NIV or invasive ventilation should be considered. Strategies should be employed to reduce further episodes of exacerbation. These include annual influenza vaccination, the prescription of long acting bronchodilators and, for those with more severe underlying disease, inhaled corticosteroids.
Chronic obstructive pulmonary disease

QUESTIONS (TRUE (T)/FALSE (F); ANSWERS AT END OF REFERENCES)

1. Regarding exacerbations of COPD:
   (A) They account for 10% of acute medical admissions in the UK
   (B) A definition including a component of health care utilisation is likely to yield a lower incidence of exacerbations than one based on change in symptoms alone
   (C) Lung function tests such as forced expiratory volume in one second provide a practical guide to severity
   (D) Viral exacerbations tend to be the most severe
   (E) Bacterial exacerbations are more common in patients with milder underlying disease

2. The following micro-organisms are commonly associated with acute exacerbations of COPD:
   (A) Haemophilus influenzae
   (B) Escherichia coli
   (C) Legionella pneumophila
   (D) Human rhinovirus
   (E) Streptococcus pneumoniae

3. Regarding the case history presented at the beginning of this review:
   (A) Prednisolone should be prescribed at 60 mg per day and continued for 10 days
   (B) Initial oxygen therapy at 4 l/min was appropriate and should continue
   (C) Salbutamol is the bronchodilator of choice at the time of acute exacerbation
   (D) The hypercapnia indicates that the patient should receive doxapram
   (E) Antibiotic prescription is inappropriate because there has been no increase in sputum volume or purulence

4. Regarding NIV at exacerbation of COPD:
   (A) It is a useful substitute for endotracheal intubation and invasive ventilation
   (B) It is superior to doxapram in the management of acute hypercapnic respiratory failure
   (C) It is usually administered as continuous positive airway pressure (CPAP)
   (D) It has a useful role in weaning patients from invasive ventilation
   (E) It is less likely to be successful in patients with pH<7.25 and these patients should be considered for immediate invasive ventilation

5. The following therapeutic modalities have been shown to reduce exacerbation frequency in patients with COPD:
   (A) Antibiotic prophylaxis
   (B) Inhaled long acting bronchodilator agents
   (C) Oral corticosteroids
   (D) Inhaled corticosteroids
   (E) Pneumococcal vaccination

REFERENCES

30. McCready DC, Brown CD. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive


www.postgradmedj.com

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are health care professionals or epidemiologists with experience in evidence based medicine and the ability to write in a concise and structured way.

Currently, we are interested in finding contributors with an interest in the following clinical areas:

- Altitude sickness; Autism; Basal cell carcinoma; Breast feeding; Carbon monoxide poisoning; Cervical cancer; Cystic fibrosis; Ecotopic pregnancy; Grief/bereavement; Halitosis; Hodigkins disease; Infectious mononucleosis (glandular fever); Kidney stones; Malignant melanoma (metastatic); Mesothelioma; Myeloma; Ovarian cyst; Pancreatitits (acute); Pancreatitits (chronic); Polymyalgia rheumatica; Post-partum haemorrhage; Pulmonary embolism; Recurrent miscarriage; Repetitive strain injury; Scoliosis; Seasonal affective disorder; Squint; Systemic lupus erythematous; Testicular cancer; Varicoseve; Viral meningitis; Vitiligo.

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Appraising the results of literature searches (performed by our Information Specialists) to identify high quality evidence for inclusion in the journal.
- Writing to a highly structured template (about 2000–3000 words), using evidence from selected studies, within 6–8 weeks of receiving the literature search results.
- Working with Clinical Evidence Editors to ensure that the text meets rigorous epidemiological and style standards.
- Updating the text every eight months to incorporate new evidence.
- Expanding the topic to include new questions once every 12–18 months.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Claire Folkes (cfolkes@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are health care professionals or epidemiologists with experience in evidence based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and health care professionals, possibly with limited statistical knowledge). Topics are usually 2000–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicaledvidence.com or contact Claire Folkes (cfolkes@bmjgroup.com).